Autopsy report · NCT04847674
A Study to Test if TEV-53275 is Effective in Relieving Asthma
Cause of deathFunding or business
“Stopped for strategic reasons”
Life of this trial
- Ran for about 1 year before it stopped.
- 97 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Sponsor type
- Industry
- Conditions
- Asthma
- Interventions
- TEV-53275 Dose A; TEV-53275 Dose B; Placebo
- Participants
- 97
- Sites
- 82
- Countries
- Canada, United States
Trials that died the same way
- A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
“The development was stopped due to company's strategy consideration” - Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
“Product development halted for business reasons.” - Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
“The study was stopped due to a realignment of strategic priorities” - A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
“The recruitment was halted for strategic reasons” - Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
“Due to strategic reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.